Development Agreement Sample Contracts

Intec Pharma Ltd. – PROCESS DEVELOPMENT AGREEMENT ACCORDION PILL™ CARBIDOPA LEVODOPA (February 27th, 2019)

[***] = Information that has been omitted and submitted separately to the Securities and Exchange Commission and for which confidential treatment has been requested.

Veracyte, Inc. – DIAGNOSTICS DEVELOPMENT AGREEMENT between Johnson & Johnson Services, Inc. and Veracyte, Inc. (February 25th, 2019)
Oxford Northeast Ltd. – Development Agreement (February 15th, 2019)

Develop and launch the ZeroVacancy.com website application (ZeroVacancy). The ZeroVacancy application will allow end users to find apartments and commercial spaces at a discount to local market rates.

Regeneron Pharmaceuticals Inc – AMENDED AND RESTATED IMMUNO-ONCOLOGY DISCOVERY AND DEVELOPMENT AGREEMENT By and Between SANOFI BIOTECHNOLOGY SAS and REGENERON PHARMACEUTICALS, INC. Effective as of December 31, 2018 (February 7th, 2019)

THIS AMENDED AND RESTATED IMMUNO-ONCOLOGY DISCOVERY AND DEVELOPMENT AGREEMENT (“Agreement”), executed on January 2, 2019 and effective as of December 31, 2018 (the “A&R Agreement Effective Date”), is by and between Sanofi Biotechnology SAS (“Sanofi”), a société par actions simplifiée, organized under the laws of France, having a principal place of business at 54, rue La Boétie, 75008 Paris, France, an indirect wholly owned subsidiary of Sanofi, a company organized under the laws of France with its principal headquarters at 54, rue La Boétie, 75008 Paris, France (“Sanofi Parent”), and Regeneron Pharmaceuticals, Inc., a corporation organized under the laws of New York and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”) (with each of Sanofi and Regeneron referred to herein individually as a “Party” and collectively as the “Parties”).

scPharmaceuticals Inc. – scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor Completed feasibility studies and advancing FUROSCIX® with the SmartDose® Drug Delivery System Forecast 2018 year-end cash of $82—$87 million and 2019 expenditures of $8—$10 million per quarter (January 29th, 2019)

BURLINGTON, Mass., January 29, 2019 (GLOBE NEWSWIRE) – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today announced it has signed a development agreement with West Pharmaceutical Services, Inc. (West) to incorporate West’s SmartDose® Drug Delivery System with FUROSCIX. FUROSCIX is scPharmaceuticals’ lead program for the treatment of edema in patients with heart failure.

Cyclerion Therapeutics, Inc. – DEVELOPMENT AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and CYCLERION THERAPEUTICS, INC. Dated as of , 2019 (January 28th, 2019)

This DEVELOPMENT AGREEMENT (this “Agreement”), dated as of        , 2019 (the “Effective Date”), is entered into by and between Ironwood Pharmaceuticals, Inc. (“Ironwood”), a Delaware corporation, and Cyclerion Therapeutics, Inc. (“Cyclerion”), a Massachusetts corporation.  “Party” or “Parties” means Ironwood or Cyclerion, individually or collectively, as the case may be.

Exactus, Inc. – Exactus Inc. Announces Entry into Hemp CBD Market Enters into Supply and Development Agreement with Ceed2Med, LLC (January 18th, 2019)

Exactus Inc. (OTCQB: EXDI) is pleased to announce its entrance into the CBD market in conjunction with Ceed2Med, LLC’s (“C2M”) acquisition of a controlling ownership interest in Exactus, Inc. and a Master Product Development and Supply Agreement with Ceed2Med, LLC for hemp-based Cannabidiol (“CBD”) products with full genetic traceability. C2M operates and manufactures at cGMP facilities and processes raw material through a number of facilities in order to produce phyto-cannabinoid rich ingredients, including isolates, distillates, water soluble, and proprietary formulations. Exactus has a number of hemp-based CBD products in the pipeline and expects to offer tinctures, edibles, capsules, topical solutions and animal health products manufactured by C2M commencing the first quarter of 2019. C2M has committed 2,500 kilograms annually to Exactus. The founders of C2M established their first CBD business in 2014 and are leaders in CBD innovation.

Cyclerion Therapeutics, Inc. – DEVELOPMENT AGREEMENT by and between IRONWOOD PHARMACEUTICALS, INC. and CYCLERION THERAPEUTICS, INC. Dated as of , 2019 (January 7th, 2019)

This DEVELOPMENT AGREEMENT (this “Agreement”), dated as of        , 2019 (the “Effective Date”), is entered into by and between Ironwood Pharmaceuticals, Inc. (“Ironwood”), a Delaware corporation, and Cyclerion Therapeutics, Inc. (“Cyclerion”), a Massachusetts corporation.  “Party” or “Parties” means Ironwood or Cyclerion, individually or collectively, as the case may be.

BAKER HUGHES a GE Co LLC – SUPPLY AND TECHNOLOGY DEVELOPMENT AGREEMENT (November 13th, 2018)

This Supply and Technology Development Agreement (as amended, modified or supplemented from time to time in accordance with its terms, the “Agreement”), entered into as of November 13, 2018 (the “Signing Date”), is made by and among General Electric Company, a New York corporation (“GE”), acting through its GE Aviation business unit and the legal entities operating on its behalf (“GE Aviation”), and Baker Hughes, a GE company, LLC, a Delaware limited liability company (“BHGE”), and General Electric Company, a New York corporation, on behalf of its GE Power business (“GE Power”).

Tandem Diabetes Care Inc – DEVELOPMENT AGREEMENT (November 9th, 2018)

This Development Agreement (this “Agreement”) is made and entered into on June 4, 2015 (the “Effective Date”) by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle St., San Diego, CA 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”).

Tandem Diabetes Care Inc – DEVELOPMENT AGREEMENT (November 1st, 2018)

This Development Agreement (this “Agreement”) is made and entered into on June 4, 2015 (the “Effective Date”) by and between Tandem Diabetes Care, Inc., a Delaware corporation, having a principal place of business at 11045 Roselle St., San Diego, CA 92121 (“Tandem”) and DexCom, Inc., a Delaware corporation, having a principal place of business at 6340 Sequence Drive, San Diego, CA 92121 (“DexCom”).

Orchard Rx Ltd – CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. OXFORD BIOMEDICA (UK) LIMITED and ORCHARD THERAPEUTICS LIMITED LICENCE AND DEVELOPMENT AGREEMENT (October 4th, 2018)

OXFORD BIOMEDICA (UK) LIMITED, a company incorporated in England and registered under number 03028927, whose registered office is at Windrush Court, Transport Way, Oxford, OX4 6LT (“BioMedica”); and

Orchard Rx Ltd – CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. OXFORD BIOMEDICA (UK) LIMITED and ORCHARD THERAPEUTICS LIMITED LICENCE AND DEVELOPMENT AGREEMENT (September 19th, 2018)

OXFORD BIOMEDICA (UK) LIMITED, a company incorporated in England and registered under number 03028927, whose registered office is at Windrush Court, Transport Way, Oxford, OX4 6LT (“BioMedica”); and

Opiant Pharmaceuticals, Inc. – CONFIDENTIALTREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION DATED: SEPTEMBER 7, 2018 AESICA QUEENBOROUGH LIMITED and OPIANT PHARMACEUTICALS INC DEVELOPMENT AGREEMENTre: development of a device capable of administering Nalmefene hydrochloride (September 10th, 2018)
Five Point Holdings, LLC – THIRD AMENDMENT TO DISPOSITION AND DEVELOPMENT AGREEMENT (Candlestick Point and Phase 2 of the Hunters Point Shipyard) (August 16th, 2018)

This THIRD AMENDMENT TO DISPOSITION AND DEVELOPMENT AGREEMENT (CANDLESTICK POINT AND PHASE 2 OF THE HUNTERS POINT SHIPYARD) (this “Third Amendment”), dated as of August 10, 2018 (the “Third Amendment Effective Date”), is entered into by and between the SUCCESSOR AGENCY TO THE REDEVELOPMENT AGENCY OF THE CITY AND COUNTY OF SAN FRANCISCO, a public body organized and existing under the laws of the State of California (the “Agency”), and CP DEVELOPMENT CO., LLC, a Delaware limited liability company (“Developer”), with reference to the following facts and circumstances:

Full House Resorts Inc – FULL HOUSE RESORTS ANNOUNCES STRONG SECOND QUARTER RESULTS - Net Revenue Grew 2.8%, Net Loss Improved 56.6%, and Adjusted EBITDA Increased 19.7% - Ferry Boat Christened at Rising Star Casino Resort; Anticipate Commencing Ferry Service This Quarter - Silver Slipper Casino & Hotel Preparing for Launch of Sports Betting Within the Next Few Weeks - Development Agreement for Expansion of Bronco Billy's Casino & Hotel Approved; Currently Finalizing Construction Contracts for Phase One of the Expansion - Submitted Letter of Intent to Participate in New Mexico Racing Commission's Competitive Process f (August 9th, 2018)

On a consolidated basis, net revenues in the second quarter of 2018 increased 2.8% to $41.2 million from $40.1 million in the prior-year period. Net loss for the second quarter of 2018 was $0.7 million, or a loss of $0.02 per diluted common share. For the second quarter of 2017, net loss was $1.5 million, or a loss of $0.07 per diluted common share. Adjusted EBITDA(a) in the 2018 second quarter grew by 19.7% to $4.4 million from $3.7 million in the second quarter of 2017.

Revance Therapeutics, Inc. – FIRST AMENDMENT TO MANUFACTURE AND DEVELOPMENT AGREEMENT (August 3rd, 2018)

This First Amendment to the Manufacture and Development Agreement by and between Bachem Americas, Inc. (formerly American Peptide Company, Inc.) (“Bachem”) located at 3132 Kashiwa Street, Torrance, CA 90505, and Revance Therapeutics, Inc. (“Revance”) located at 7555 Gateway Boulevard, Newark, CA 94560, is effective as of the date of the final signature below (the “First Amendment Effective Date”).

Aridis Pharmaceuticals, Inc. – FORMULATION DEVELOPMENT AGREEMENT (July 18th, 2018)

This FORMULATION DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of June l, 2007 (the “Effective Date”) by and between Aridis Pharmaceuticals, LLC, a California corporation with its business at 5941 Optical Court, San Jose, CA 95138 (“Aridis”) and PATH Vaccine Solutions, a nonprofit organization and affiliate of PATH organized as a separate legal entity under the laws of the State of Washington, having a primary place of business at 1455 NW Leary Way, Seattle, WA 98107 (“PVS”).

Zander Therapeutics, Inc – COLLABORATION AND DEVELOPMENT Agreement (July 10th, 2018)

This Collaboration Agreement (“Agreement”) is made as of July 5, 2018 (the “Effective Date”) by and between Ampersand Biopharmaceuticals, Inc, a Delaware corporation with offices located at 2545 W. Hillcrest Dr., Thousand Oaks, CA 91320 (“Ampersand”), and Zander Therapeutics, Inc. a Nevada corporation, with offices located at 4700 Spring Street, Suite 304 La Mesa, CA, 91942, USA (“Zander”). Ampersand and Zander are sometimes referred to in this Agreement individually as a “Party”, and collectively as the “Parties”.

Entest Group, Inc. – COLLABORATION AND DEVELOPMENT Agreement (July 10th, 2018)

This Collaboration Agreement (“Agreement”) is made as of July 5, 2018 (the “Effective Date”) by and between Ampersand Biopharmaceuticals, Inc, a Delaware corporation with offices located at 2545 W. Hillcrest Dr., Thousand Oaks, CA 91320 (“Ampersand”), and Zander Therapeutics, Inc. a Nevada corporation, with offices located at 4700 Spring Street, Suite 304 La Mesa, CA, 91942, USA (“Zander”). Ampersand and Zander are sometimes referred to in this Agreement individually as a “Party”, and collectively as the “Parties”.

Innovative Industrial Properties Inc – DEVELOPMENT AGREEMENT (May 31st, 2018)

THIS DEVELOPMENT AGREEMENT is made and entered into effective this 31st day of May, 2018 (the “Effective Date”), by and between IIP-MA 1 LLC, a Delaware limited liability company (“Landlord”), PHARMACANNIS MASSACHUSETTS INC., a Massachusetts corporation (“Tenant”), and IIP OPERATING PARTNERSHIP, LP, a Delaware limited partnership (“Parent Company”). Landlord, Tenant and Parent Company shall sometimes collectively be referred to herein as the “Parties.”

HotApp Blockchain Inc. – OUTSOURCE TECHNOLOGY DEVELOPMENT AGREEMENT (May 15th, 2018)

This Outsource Technology Development Agreement (this “Agreement”) is entered into and effective as of this 1st day of March, 2018 (the “Effective Date”) by and between Document Security Systems, Inc., a corporation organized and existing under the laws of the State of New York (“DSS”), and HotApp International Ltd., a corporation organized and existing under the laws of Hong Kong (“Developer”).

Tapinator, Inc. – GAME ENGINE AND GAME-SPECIFIC DEVELOPMENT AGREEMENT (April 30th, 2018)

This Game Engine and Game-Specific Development Agreement (this “Agreement”) is entered into as of June 17, 2014, by and between Tapinator, Inc., a public Delaware corporation (the “Company”), and Khurram Samad (“KS”).

Aridis Pharmaceuticals, Inc. – FORMULATION DEVELOPMENT AGREEMENT (April 20th, 2018)

This FORMULATION DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of June l, 2007 (the “Effective Date”) by and between Aridis Pharmaceuticals, LLC, a California corporation with its business at 5941 Optical Court, San Jose, CA 95138 (“Aridis”) and PATH Vaccine Solutions, a nonprofit organization and affiliate of PATH organized as a separate legal entity under the laws of the State of Washington, having a primary place of business at 1455 NW Leary Way, Seattle, WA 98107 (“PVS”).

Sea Ltd – AMENDED AND RESTATED MOBILE GAME DEVELOPMENT AGREEMENT (Cover Page) (April 11th, 2018)

This Amended and Restated Mobile Game Development Agreement, which consists of this Cover Page, the Terms and Conditions attached as Attachment 1 and the other Attachments listed above, each of which are incorporated by reference (collectively, the “Agreement”) is entered into as of the Effective Date and amended and restated as of 8 March 2018 between Tencent and Garena. This Agreement is effective as of the Effective Date and contains the terms and conditions under which Garena grants Tencent the right to make available Branded Games.

AeroVironment Inc – DESIGN AND DEVELOPMENT AGREEMENT (STEP 2) (March 7th, 2018)

This Step 2 Design and Development Agreement (this “Agreement”) is entered into as of, 2017 (the “Effective Date”) by and between HAPSMobile Inc., a Japanese corporation having its principal place of business at 1-9-1 Higashi-Shimbashi, Minato-ku, Tokyo, Japan (“HAPSMobile”) and AeroVironment, Inc., a Delaware corporation having its principal place of business at 800 Royal Oaks Drive, Suite 210, Monrovia, CA 91016, U.S.A. (“AV”). HAPSMobile and AV hereinafter will be referred to individually as “Party” and collectively as “Parties”.

MARRIOTT VACATIONS WORLDWIDE Corp – FIRST AMENDMENT TO LICENSE, SERVICES, AND DEVELOPMENT AGREEMENT (FOR RITZ- CARLTON PROJECTS) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this “Amendment”) is executed as of February 26, 2018 by The Ritz-Carlton Hotel Company, L.L.C., a Delaware limited liability company (“Licensor”), and Marriott Vacations Worldwide Corporation, a Delaware corporation (“Licensee”).

MARRIOTT VACATIONS WORLDWIDE Corp – FIRST AMENDMENT TO LICENSE, SERVICES, AND DEVELOPMENT AGREEMENT (FOR MARRIOTT PROJECTS) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this “Amendment”) is executed as of February 26, 2018 by Marriott International, Inc., a Delaware corporation (“MII”), and Marriott Worldwide Corporation, a Maryland corporation (“MWC”) (MII and MWC are referred to collectively herein as “Licensor”), and Marriott Vacations Worldwide Corporation, a Delaware corporation (“Licensee”).

Marriott International Inc /Md/ – FIRST AMENDMENT TO LICENSE, SERVICES, AND DEVELOPMENT AGREEMENT (FOR RITZ- CARLTON PROJECTS) (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this “Amendment”) is executed as of February 26, 2018 by The Ritz-Carlton Hotel Company, L.L.C., a Delaware limited liability company (“Licensor”), and Marriott Vacations Worldwide Corporation, a Delaware corporation (“Licensee”).

Marriott International Inc /Md/ – FIRST AMENDMENT TO LICENSE, SERVICES, AND DEVELOPMENT AGREEMENT (February 27th, 2018)

This First Amendment to License, Services, and Development Agreement (this “Amendment”) is executed as of February 26, 2018 by Marriott International, Inc., a Delaware corporation (“MII”), and Marriott Worldwide Corporation, a Maryland corporation (“MWC”) (MII and MWC are referred to collectively herein as “Licensor”), and Marriott Vacations Worldwide Corporation, a Delaware corporation (“Licensee”).

STERLING CONSOLIDATED Corp – TOKEN DEVELOPMENT AGREEMENT (February 2nd, 2018)

This Token Development Agreement (“Agreement”) is made as of January 29, 2018, by and between UPGRADE DIGITAL INC. d/b/a BlockchainDriven, a New York corporation with an address at 33 W. 19th Street, New York, NY 10001 (“Developer”) and STERLING CONSOLIDATED CORP., a Nevada corporation with an address at 1105 Green Grove Road, Neptune City, NJ 07753 (“STCC”)

Gaming Partners International CORP – FOR IMMEDIATE RELEASE For Further Information, Contact: Gregory S. Gronau, President and Chief Executive Officer PH: 702.384.2425 FX: 702.384.1965 Gaming Partners International Corporation, BrainChip Inc., and Xuvi, LLC Signed Licensing and Development Agreement (January 31st, 2018)

North Las Vegas, NV (PR Newswire) (January 31, 2018) — Gaming Partners International Corporation (NASDAQ: GPIC), a worldwide leading provider of casino table products, currency, and radio frequency identification (RFID) solutions, has entered global licensing and development agreements to develop an advanced Automated Table Solution (ATS) with BrainChip Holdings Ltd. (ASX:BRN), a leading developer of accelerated solutions for artificial intelligence (AI) applications, and with Xuvi, LLC, a data science company that uses immersive data analytics and automation for intelligent data-driven decisions.

Tfi Tab Gida Yatirimlari A.S. – AMENDED AND RESTATED DEVELOPMENT AGREEMENT Dated 5 June 2002 as previously amended by the First Amendment on 27 May 2013 and as amended and restated on 22 January 2018 among (January 29th, 2018)

THIS AMENDED AND RESTATED DEVELOPMENT AGREEMENT (this “Agreement”) dated 5 June 2002 as previously amended by the First Amendment on 27 May 2013 and as amended and restated on 22 January 2018 with effect from the Effective Date (defined below), is made and delivered as a deed among:

Tfi Tab Gida Yatirimlari A.S. – AMENDED AND RESTATED DEVELOPMENT AGREEMENT Dated 5 June 2002 as previously amended by the First Amendment on 27 May 2013 and as amended and restated on 22 January 2018 among (January 22nd, 2018)

THIS AMENDED AND RESTATED DEVELOPMENT AGREEMENT (this “Agreement”) dated 5 June 2002 as previously amended by the First Amendment on 27 May 2013 and as amended and restated on 22 January 2018 with effect from the Effective Date (defined below), is made and delivered as a deed among:

Tfi Tab Gida Yatirimlari A.S. – MASTER FRANCHISE AND DEVELOPMENT AGREEMENT (January 18th, 2018)